{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7fv9MIDA","lastupdate":"2023-09-04T00:00:00.000Z","update_date":"2023-09-04T00:00:00.000Z","lastModified":"Sep 14, 2024","active":1,"confidence_score":99,"confidence_score_reason":"markets","urlname":"neuroderm","minimal_profile":null,"status":"Acquired","fullstatus":"Acquired by Mitsubishi Tanabe Pharma Corporation on Jul, 2017","acquired":1,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$W0Azss9e5EnaRMfTb7366jcDJu64lF7cEW749Jcm8gcNCpWaptjH9V","name":"NeuroDerm","oneliner":"Drug-device Combination Solutions for Central Nervous System Disorders","registrar":"513394577","website":"https://neuroderm.com","careerspage":"https://neuroderm.com/careers/current-openings/","founded_month":3,"founded_year":2003,"formernames":[],"sociallinks":{"twitter":"","youtube":"https://www.youtube.com/@neuroderm8966","facebook":"","linkedin":"https://www.linkedin.com/company/9873432","instagram":""},"social":["https://www.youtube.com/@neuroderm8966","https://www.linkedin.com/company/9873432"],"flattenedsociallinks":"https://www.youtube.com/@neuroderm8966|https://www.linkedin.com/company/9873432","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"51-200","employees_exact":171,"patent":1,"raised":63500000,"stage":"Acquired","public_stage":"Acquired","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"NeuroDerm specializes in integrating proprietary pharmaceutical formulations, state-of-the-art delivery system, and digital health solutions with the aim of reducing disease burden and improving the quality of life of patients and their families.\n\nNeuroDerm’s flagship product ND0612 is currently in late stage development for Parkinson’s disease patients experiencing motor fluctuations. Its system for self-administered continuous subcutaneous infusion of the gold standard levodopa/carbidopa, was designed specifically to be a user-friendly system for people with Parkinson's disease, to maintain steady therapeutic levodopa plasma concentrations for the purpose of improving fluctuations, that is, reducing patients’ \"OFF\" time without increasing troublesome dyskinesia.\n\nIts tailored solution potentially offers sustained relief (compared to oral immediate-release levodopa/carbidopa treatments) and empowers patients and their families to regain control of their lives with greater daily-life predictability and independence.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97289462729","country":null,"address":{"israeli":[{"id":"6b82b6f0-7d1e-458a-bfe2-89ddb2a5dd82","city":"Rehovot","type":null,"address":"Prof. Haim Pekeris 3, Rehovot, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"A6KREguWnVe1Kktdp3Oi8UNkC8IZOc4Bll8qPFV20mK2NiPSLFX0Qt","date":"Jan 9, 2023","link":"https://www.prnewswire.com/news-releases/neuroderm-announces-highly-positive-results-from-the-pivotal-phase-iii-boundless-trial-evaluating-nd0612-in-parkinsons-disease-patients-with-motor-fluctuations-301715848.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Clinical Trials, Parkinsons Disease Treatment","company":"NeuroDerm Ltd.","layoffs":"N/A","summary":"NeuroDerm Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation, announced positive results from the Phase III BouNDless trial of ND0612, a continuous 24-hour infusion of levodopa/carbidopa for Parkinsons Disease patients with motor fluctuations. The trial met its primary endpoint of Good ON time, demonstrating superior efficacy over oral levodopa/carbidopa. Only 6.3% of patients discontinued the trial, with 5.5% due to adverse events. The results suggest ND0612 could be an effective treatment strategy for Parkinsons disease patients with motor fluctuations. Submissions to regulatory authorities are anticipated in the United States this year and later in the European Union.","partners":"Mitsubishi Tanabe Pharma Corporation","customers":"Parkinsons Disease Patients","investors":"Mitsubishi Tanabe Pharma Corporation","confidence":9,"key_topics":["ND0612 Efficacy","Phase III Trial","Parkinsons Disease Treatment","Motor Fluctuations","Treatment Innovation"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers","acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Q0twAFP97pYaHKT7i7ThnRoll0k3dFzkVN5peqo4XsgJyfbRMJLmgL","news_summary":"NeuroDerm Announces Highly Positive Results from the Pivotal Phase III BouNDless Trial Evaluating ND0612 in Parkinson's Disease Patients with Motor Fluctuations","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"dd9a73de-6de5-4ae5-af3b-ba382767cfc1","date":"Aug 28, 2019","link":"https://www.prnewswire.com/news-releases/phase-3-clinical-trial-evaluating-continuous-subcutaneous-carbidopalevodopa-nd0612-initiated-in-the-united-states-for-parkinsons-disease-with-motor-fluctuations-300908477.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"clinical trial","company":"Mitsubishi Tanabe Pharma America, Inc.","layoffs":null,"summary":"Mitsubishi Tanabe Pharma America, Inc. has announced the initiation of the Phase 3 BouNDless study to investigate the efficacy of ND0612, a potential non-surgical continuous treatment for Parkinsons disease. The study aims to compare the treatment to oral immediate-release carbidopa/levodopa (CD/LD) in patients experiencing motor fluctuations. The company recognizes the limitations of current therapeutic options and hopes to develop a treatment that stabilizes CD/LD plasma levels and alleviates motor fluctuations. The clinical development of ND0612 is being led by NeuroDerm, and if regulatory approval is obtained, Mitsubishi Tanabe Pharma America intends to commercialize the therapy in the U.S. The study design will be presented at an upcoming conference. Mitsubishi Tanabe Pharma America is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation.","partners":["NeuroDerm, Ltd."],"customers":null,"investors":null,"confidence":9,"key_topics":["Parkinsons disease","Phase 3 study","ND0612","motor fluctuations","continuous treatment"],"date_of_event":"August 28, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"CKl7PNPpczS5fDdwD4ow3ECgsD13jYghyn84RGrLjKeUslK1FqWy1q","news_summary":"Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated In The United States For Parkinson's Disease With Motor Fluctuations","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"74bc698d-5088-467c-a39a-ccef3aeb76eb","date":"Jul 24, 2017","link":"https://globenewswire.com/news-release/2017/07/24/1055926/0/en/NeuroDerm-Enters-Definitive-Agreement-to-be-Acquired-by-Mitsubishi-Tanabe-Pharma-Corporation-for-US-1-1-Billion-in-Cash.html","source":"globenewswire.com","visible":1,"analysis":{"tags":"acquisition","company":"NeuroDerm Ltd.","layoffs":null,"summary":"NeuroDerm Ltd. has signed a definitive agreement to be acquired by Mitsubishi Tanabe Pharma Corporation for $39 per share in cash. The transaction, which has received unanimous approval by NeuroDerms Board of Directors, implies an equity value of approximately $1.1 billion. The acquisition is expected to benefit NeuroDerms shareholders and Parkinsons disease patients by making new therapies available more rapidly. The transaction is subject to approval by NeuroDerms shareholders and regulatory authorities, and is expected to close in the fourth quarter of 2017. Centerview Partners, LLC is acting as financial advisor to NeuroDerm.","partners":null,"customers":null,"investors":"Mitsubishi Tanabe Pharma Corporation","confidence":9,"key_topics":["NeuroDerm","Mitsubishi Tanabe Pharma Corporation","acquisition","Parkinsons disease","clinical stage pharmaceutical company"],"date_of_event":"July 24, 2017","valuation_amount":"$1.1 billion","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oTYpz1bbTaLFNgOaJcZCNYMJGPqcBBrGmwZPanxE21l3JPQcFS1e70","news_summary":"NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"54582d29-3707-4d84-9c51-ad8d5974e956","date":"Jun 13, 2017","link":"http://www.globes.co.il/en/article-neuroderm-mulls-several-acquisition-offers-1001192363","source":"www.globes.co.il","visible":1,"analysis":{"tags":"acquisition","company":"Neuroderm","layoffs":null,"summary":"Neuroderm, an Israeli drug delivery company, saw a 14% increase in its share price following reports that it was considering acquisition offers. The company has received several offers and has begun the initial examination process with potential buyers. Neuroderm has a market cap of $658 million and is seeking a substantial premium on its market price. The potential buyers are pharma companies in the neurology sector. Neuroderm has developed a unique method of delivering drugs through the skin and its leading products are new formulations of Levodopa. The company obtained an exemption from multi-center Phase III trials for registering its product from the US FDA. Neuroderms main shareholders include Sequoia Capital, Omrix Biopharmaceuticals founder Robert Taub, former GE executive Uwe Wascher, Prof. Shmuel Cabilly, Redmile Capital Fund, and CEO Oded Lieberman.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Neuroderm","acquisition","pharma companies","drug delivery","market cap"],"date_of_event":"June 13, 2017","valuation_amount":"$658 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"q9QmjT42mxprMHGAEQBjnjepfKnO76j0Wshz82YHvoYiWQf6InD10D","news_summary":"Neuroderm mulls several acquisition offers","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"34da08a7-d4ac-4baa-bcae-9699317f7c81","date":"Mar 2, 2017","link":"http://www.globes.co.il/en/article-neuroderm-jumps-on-successful-trial-results-1001179272","source":"www.globes.co.il","visible":1,"analysis":{"tags":"drug trial","company":"Neuroderm","layoffs":null,"summary":"Neuroderm has announced success in an open trial of its drug for treatment of Parkinsons Disease. The trial results showed that the companys product reduces the patients average off time from 5.5 hours a day before the trial, after receiving the currently accepted treatment, to 2.7 hours after treatment with the drug. The companys share price jumped 22% on the news, boosting Neuroderms market cap to $749 million, a record for the company and the highest market cap for a purely Israeli biomed company currently listed on Nasdaq. Neuroderm has since conducted two offerings, each at a higher price than its predecessor. The company is changing its development plan for Europe based on the trial results.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Parkinsons Disease","clinical trial","drug delivery","market cap","share price"],"date_of_event":"March 2, 2017","valuation_amount":"$749 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"yLQdYKBGPOI4i2cE8VSWAXWlhlk9PpqWrJlSBMTumUmGchALQc7WVU","news_summary":"Neuroderm jumps on successful trial results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8bd6892f-fce7-4065-b6a4-984ff538290c","date":"Jul 16, 2015","link":"http://www.globes.co.il/en/article-neuroderm-raises-67m-in-nasdaq-secondary-offering-1001053629","source":"www.globes.co.il","visible":1,"analysis":{"tags":"drug delivery system","company":"NeuroDerm","layoffs":null,"summary":"NeuroDerm, an Israeli drug development company, has raised $67 million in a secondary offering on Nasdaq. The company has developed a drug delivery system for treating Parkinsons Disease. The offering was 16% more than planned, with the potential to reach $75.5 million. NeuroDerms shares rose 8.3% on Nasdaq following the offering. The company previously raised $45 million in its IPO. NeuroDerms principal shareholders include chairman Robert Taub, Uwe Wascher, and Prof. Shmuel Cabilly. The companys clinical plan includes trials against the oral drug and testing the levels of the product in the blood. Results are expected by the end of the year, with hopes of product approval in 2018.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["drug delivery system","Parkinsons Disease","secondary offering","underwriters","share price"],"date_of_event":"July 16, 2015","valuation_amount":"$365 million","impact_on_company":"growth-positive","investment_amount":"$67 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"hR3Lv9OUyuIqR0bQzicLWCqZdhdWURCZsu1j6rjDCa81A8QEfUZTNy","news_summary":"NeuroDerm raises $67m in Nasdaq secondary offering","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"42444d57-baca-4c2e-b75e-8210433ba319","date":"Jul 14, 2015","link":"http://www.globes.co.il/en/article-neuroderm-ups-nasdaq-secondary-offering-to-58m-1001052933","source":"www.globes.co.il","visible":1,"analysis":{"tags":"drug delivery","company":"NeuroDerm","layoffs":null,"summary":"NeuroDerm plans to raise $58 million in a secondary offering at a share price of $15.60. The company has developed a system for subcutaneous delivery of drugs for Parkinsons Disease and is conducting clinical trials. NeuroDerms market cap is currently $272 million.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["secondary offering","share price","underwriters","principal shareholders","clinical plan"],"date_of_event":"July 14, 2015","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$58 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9F52LnVoxV0Ocq7Z8xuwFLUmA9bmAUThe3yD33xemIFS4kFOT5J7Ik","news_summary":"NeuroDerm ups Nasdaq secondary offering to $58m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4a82fa00-3aff-4874-89ca-0247d2509c8d","date":"Dec 30, 2014","link":"http://www.reuters.com/article/2014/12/30/us-neuroderm-study-idUSKBN0K810K20141230","source":"www.reuters.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"c4jo5CrfiBvd4bpUoGaGotyIpSAl9xEIE3Xp3kWcz1Db6D1KLQHgU7","news_summary":"http://www.reuters.com/article/2014/12/30/us-neuroderm-study-idUSKBN0K810K20141230","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"2940fa54-f83a-4903-8984-4ac44ac7aeca","date":"Nov 14, 2014","link":"http://www.globes.co.il/en/article-neuroderm-nasdaq-ipo-disappoints-1000986374","source":"www.globes.co.il","visible":1,"analysis":{"tags":"IPO, Underperformance","company":"NeuroDerm","layoffs":"N/A","summary":"NeuroDerm, a Rehovot-based company that has developed a transdermal drug delivery system for the treatment of Parkinsons disease, had a disappointing IPO on Nasdaq. The company raised only $45 million by issuing 4.5 million shares at $10 per share, giving it a company value of $164 million. This is significantly less than the $58-72 million at a company value of $290 million that NeuroDerm had sought to raise.","partners":"Jefferies, Cowen & Company, Oppenheimer, Roth Capital","customers":"N/A","investors":"Robert Taub, Uwe Wascher, Prof. Shmuel Cabilly, Capital Point Ltd.","confidence":9,"key_topics":["IPO","Parkinsons Disease","Drug Development","Underperformance","Clinical Trials"],"date_of_event":"November 14, 2014","valuation_amount":"$164 million","impact_on_company":"growth-negative","investment_amount":"$45 million","structured_issues":["Public Trading","Investment"],"acquisition_amount":"N/A","structuredIssuesShow":"#Public Trading  #Investment","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"0PHSM8EoM1qdPbsxewL21rY8GlSRU7GEa3Tncauotk89mX0vCSZclf","news_summary":"NeuroDerm Nasdaq IPO disappoints","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"86bb62de-fdd9-42b7-a004-a914ec84fa45","date":"Nov 3, 2014","link":"http://www.globes.co.il/en/article-neuroderm-set-for-60-82m-nasdaq-ipo-1000983690","source":"www.globes.co.il","visible":1,"analysis":{"tags":"IPO","company":"NeuroDerm","layoffs":null,"summary":"NeuroDerm, a central nervous system drug developer, has filed a revised prospectus with the US SEC and announced the value of its IPO on Nasdaq. The company plans to raise between $60-82 million at a value of $236-290 million. NeuroDerm has developed a transdermal drug delivery system for the treatment of Parkinsons disease. The companys lead products achieve better results in maintaining uniform levels of the drug in the bloodstream, enabling more effective treatment with fewer side effects. NeuroDerms main shareholders include Omrix Biopharmaceuticals founder Robert Taub, Uwe Wascher, and Prof. Shmuel Cabilly. The company has raised $17.8 million in a private placement and has no revenue as it is still in the R&D stage. A rival company in the field, Civitas, was recently sold for $525 million.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["transdermal drug delivery system","Parkinsons disease","IPO","shareholders","rival company"],"date_of_event":"November 3, 2014","valuation_amount":"$236-290 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PcEbs5ZtDWScPmJnaI0vcOffBlTzhwX3xwBijHYgp1lcbS9a4mltkA","news_summary":"NeuroDerm set for $60-82m Nasdaq IPO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":10,"techcommunityinvolvement":null,"mediagallery":[{"id":"lJZin3nUpij6nbvsAvKTJHFgk0RIbiakseOxFOIcl9BE69sndxPAbp","timestamp":"2023-09-04 17:41:15.000000","resources_type":2,"resources_title":"","resources_file_name":"AxXo8TOeo4U","alt":"","imageurl":"https://img.youtube.com/vi/AxXo8TOeo4U/0.jpg","url":"http://youtu.be/AxXo8TOeo4U"}],"tags":["pharmaceuticals","neurology","parkinson","drug-design","drug-delivery","drug-discovery","pharma-companies","biopharmaceutical","medical-devices","patients","biotechnology"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":[{"date":"2017-10-18","name":"Continuous, transdermal, non-intrusive delivery of L-Dopa","tags":["pharmaceuticals","parkinson"],"category":"Pharmaceuticals & Diagnostics","tto_logo":"/image_cloud/bgn-technologies1_tto_logo_d432a8a3-6016-11e8-8ef8-41fdcbb0dda6","university_logo":"/image_cloud/bgn-technologies1_institution_logo_d432a8a3-6016-11e8-8ef8-41fdcbb0dda6"},{"date":"2003-03-01","name":"Liquid formulation of levodopa/carbidopa (LD/CD)","tags":["pharmaceuticals","degenerative-diseases","neurology","parkinson","treatments"],"category":"Pharmaceuticals & Diagnostics","tto_logo":"/image_cloud/bgn-technologies1_tto_logo_d432a8a3-6016-11e8-8ef8-41fdcbb0dda6","university_logo":"/image_cloud/bgn-technologies1_institution_logo_d432a8a3-6016-11e8-8ef8-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["Levodopa","Carbidopa"],"geomarkets":["United States"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":2,"lastfunding":"$45M","totalrounds":3,"fundingstage":"Acquired","totalfunding":"$63.5M","publicinvestors":2,"lastpublicfunding":45000000,"totalpublicrounds":3,"totalpublicfunding":63500000},"team":[{"name":"Kengo Isshiki","email":"kengo@neuroderm.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4OGgxMgJDA","bounced":false,"claimed":0,"founder":0,"urlname":"kengo-isshiki-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDggZewowgM","position":"CEO","last_name":"Isshiki","claimtoken":"5fc8822a89123abeb3b5dc72518dde93712082ae2f1030e1ee43c7a439b259a4","first_name":"Kengo","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/kengo-isshiki-25a960187/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-06-29 10:25:42.000000","initials":"KI","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Oded Lieberman","email":"","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgN7EzJUIDA","bounced":false,"claimed":0,"founder":0,"urlname":"ayelet-altman","visible":0,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICA3vaapgkM","position":"CEO - Left the company","last_name":"Lieberman","claimtoken":"00b8916a8f1fe17200e42743af465b404a14165b3d56bb0ba9d94c36831f18c1","first_name":"Oded","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/olieberman","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2020-06-29 05:21:59.000000","initials":"OL","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/internal-visibility.svg\"/>\n    <text>private</text>\n</div>'"},{"name":"Uri David","email":"uri@neuroderm.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4OHnzKcKDA","bounced":false,"claimed":0,"founder":0,"urlname":"uri-david-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgwYugxQgM","position":"CTO","last_name":"David","claimtoken":"Zz041gsOhKr2vLKIRfxzOTdr6lTPGsOWkh4lr2MMHYrt7ClO2oAV3k","first_name":"Uri","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/uri-david-9b1b6216/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-09-04 17:43:16.000000","initials":"UD","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Anat Nahmany","email":"anat@neuroderm.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoKmC-o4IDA","bounced":false,"claimed":0,"founder":0,"urlname":"anat-nahmany","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgqYLsxwoM","position":"VP HR","last_name":"Nahmany","claimtoken":"c7a3f5d919f21efe400b9031a7a4950648e8963dc12223ec885da94ff8aa849b","first_name":"Anat","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/anat-nahmany-3a9ba11","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-06-29 05:22:42.000000","initials":"AN","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Nati Hoter Ishay","email":"nati@neuroderm.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4MGG3sQIDA","bounced":false,"claimed":1,"founder":0,"urlname":"nati-hoter-ishay","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDggc3zpgkM","position":"Human Resources","last_name":"Hoter Ishay","claimtoken":"41b2b0924c7bf171d2a1667be4b9113b1b7498c5d442414a80cae018ed04e230","first_name":"Nati","picturekey":null,"claimeddate":"2020-06-29","linkedinurl":"https://www.linkedin.com/in/nati-hoter-ishay-98795217b/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-06-29 10:18:45.000000","initials":"NH","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverifydate":"2019-09-08T00:00:00.000Z","crunchbaseid":"NeuroDerm","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Jenny Sotnik-Talisman","creator_email":"genys30@yahoo.com","createdate":"2014-08-24T00:00:00.000Z","biverification":"Sharon Shapira","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDInfi5Cww","date":"Oct 2017","amount":"Undisclosed","source":"https://sec.report/Ticker/NDRM","ticker":null,"eventtype":"DelistingEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","duetoacquisition":"","isdelisting":1,"acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD429W_Cww","date":"Jul 2017","amount":"$1.1B","source":"Migrated","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Mitsubishi Tanabe Pharma Corporation","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3qCAw","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/mitsubishi-tanabe-pharma-corporation","acquiredcompany_mna_logokey":"$w9EV3NgzPOtQvPpmoYoK0JOLgx85nZvz2SvWJypyx50UCVT5gtnNQg","acquiredcompany_mna_urlname":"/company_page/mitsubishi-tanabe-pharma-corporation","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$w9EV3NgzPOtQvPpmoYoK0JOLgx85nZvz2SvWJypyx50UCVT5gtnNQg","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":1100000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCImt_yCQw","date":"Nov 2014","amount":"Undisclosed","source":"","ticker":"NDRM","eventtype":"POEvent","valuation":"$164M","investment":[],"capitalraised":"$45M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":45000000,"valuationnumber":164000000},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODE9ujCCQw","date":"Aug 2014","amount":"$16M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"The Elias Group","type":"Investor","amount":0,"hidden":false,"country":"South Korea","fullurl":"/investor_page/the-elias-group","logokey":"$5tNBGtUz1yu3L8CtNmxWCORXsGVlWa4ODIPP0vM8oGgMNAp3AbQtOo","tagline":"","urlname":"/investor_page/the-elias-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODkwNalCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"59fd9817-c4ae-4698-894b-7048a69cb21a","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$5tNBGtUz1yu3L8CtNmxWCORXsGVlWa4ODIPP0vM8oGgMNAp3AbQtOo","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":16000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEv6CnCgw","date":"Jul 2007","amount":"$2.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Robert Taub","type":"Investor","amount":0,"hidden":false,"country":"Belgium","fullurl":"/investor_page/robert-taub","logokey":"$i2LoB1soqa6gyyWs8RhxWl5OTfS7ifukgM6ak4srcWkJNPp3fduHEr","tagline":"","urlname":"/investor_page/robert-taub","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEqLCDCgw","fundingtype":"Angel","leadpartner":null,"investmentid":"120924dd-55b2-4e3f-8b80-6461680d5f34","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$i2LoB1soqa6gyyWs8RhxWl5OTfS7ifukgM6ak4srcWkJNPp3fduHEr","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"3/2003","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"NeuroDerm","logourl":"https://storage.googleapis.com/clean-finder-353810/$W0Azss9e5EnaRMfTb7366jcDJu64lF7cEW749Jcm8gcNCpWaptjH9V","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$W0Azss9e5EnaRMfTb7366jcDJu64lF7cEW749Jcm8gcNCpWaptjH9V","seoabout":"NeuroDerm specializes in integrating proprietary pharmaceutical formulations, state-of-the-art delivery system, and digital health solutions with the aim o...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":5,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDInfi5Cww","date":"Oct 2017","amount":"Undisclosed","source":"https://sec.report/Ticker/NDRM","ticker":null,"eventtype":"DelistingEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","duetoacquisition":"","isdelisting":1,"acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD429W_Cww","date":"Jul 2017","amount":"$1.1B","source":"Migrated","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Mitsubishi Tanabe Pharma Corporation","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3qCAw","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/mitsubishi-tanabe-pharma-corporation","acquiredcompany_mna_logokey":"$w9EV3NgzPOtQvPpmoYoK0JOLgx85nZvz2SvWJypyx50UCVT5gtnNQg","acquiredcompany_mna_urlname":"/company_page/mitsubishi-tanabe-pharma-corporation","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$w9EV3NgzPOtQvPpmoYoK0JOLgx85nZvz2SvWJypyx50UCVT5gtnNQg","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":1100000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCImt_yCQw","date":"Nov 2014","amount":"Undisclosed","source":"","ticker":"NDRM","eventtype":"POEvent","valuation":"$164M","investment":[],"capitalraised":"$45M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":45000000,"valuationnumber":164000000}],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODE9ujCCQw","date":"Aug 2014","amount":"$16M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"The Elias Group","type":"Investor","amount":0,"hidden":false,"country":"South Korea","fullurl":"/investor_page/the-elias-group","logokey":"$5tNBGtUz1yu3L8CtNmxWCORXsGVlWa4ODIPP0vM8oGgMNAp3AbQtOo","tagline":"","urlname":"/investor_page/the-elias-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODkwNalCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"59fd9817-c4ae-4698-894b-7048a69cb21a","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$5tNBGtUz1yu3L8CtNmxWCORXsGVlWa4ODIPP0vM8oGgMNAp3AbQtOo","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":16000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEv6CnCgw","date":"Jul 2007","amount":"$2.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Robert Taub","type":"Investor","amount":0,"hidden":false,"country":"Belgium","fullurl":"/investor_page/robert-taub","logokey":"$i2LoB1soqa6gyyWs8RhxWl5OTfS7ifukgM6ak4srcWkJNPp3fduHEr","tagline":"","urlname":"/investor_page/robert-taub","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEqLCDCgw","fundingtype":"Angel","leadpartner":null,"investmentid":"120924dd-55b2-4e3f-8b80-6461680d5f34","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$i2LoB1soqa6gyyWs8RhxWl5OTfS7ifukgM6ak4srcWkJNPp3fduHEr","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}